Acrivon Therapeutics (ACRV) Expected to Release Quarterly Earnings on Thursday

Acrivon Therapeutics (NASDAQ:ACRV) is projected to post its Q3 2026 resultson Thursday, November 12th. Analysts expect Acrivon Therapeutics to announce earnings of ($0.45) per share and revenue of $0.50 million for the quarter. Investors may visit the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Monday, November 9, 2026 at 4:00 PM ET.

Acrivon Therapeutics (NASDAQ:ACRV) last released its quarterly earnings results on Wednesday, August 12th. The company reported ($0.43) EPS for the quarter, beating analysts’ consensus estimates of ($0.50) by $0.07. On average, analysts expect Acrivon Therapeutics to post ($1.76) EPS for the current fiscal year and ($1.40) EPS for the next fiscal year.

Acrivon Therapeutics Trading Up 4.2%

Shares of ACRV stock opened at $1.74 on Thursday. Acrivon Therapeutics has a 1-year low of $1.27 and a 1-year high of $3.56. The stock has a market cap of $74.56 million, a price-to-earnings ratio of -0.93 and a beta of 1.96. The stock has a 50-day moving average of $1.91 and a 200-day moving average of $1.76.

Insider Transactions at Acrivon Therapeutics

In related news, CEO Peter Blume-Jensen sold 14,036 shares of the business’s stock in a transaction on Tuesday, August 25th. The shares were sold at an average price of $2.21, for a total value of $31,019.56. Following the transaction, the chief executive officer owned 2,230,052 shares in the company, valued at $4,928,414.92. The trade was a 0.63% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 17,345 shares of company stock valued at $37,578 in the last quarter. 10.50% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

ACRV has been the topic of several analyst reports. Wall Street Zen upgraded Acrivon Therapeutics from a “sell” rating to a “hold” rating in a report on Monday, October 5th. Weiss Ratings raised shares of Acrivon Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, October 9th. Three investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Acrivon Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $13.50.

Acrivon Therapeutics Company Profile

Acrivon Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing precision oncology medicines for patients with difficult-to-treat cancers. The company uses its proprietary OncoSignature platform to identify tumor characteristics that may predict a patient’s response to a particular therapy, with the goal of matching treatments to the patients most likely to benefit.

Acrivon’s lead investigational product is ACR-368, an oral small-molecule therapy designed to target cell-cycle checkpoint mechanisms that cancer cells rely on for survival.